Teva’s Copaxone Suit Is “Absolutely Unprecedented,” FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says Teva’s argument to court about dire impact of potential glatiramer ANDAs does not match its statements to investors.